These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

7117 related items for PubMed ID: 22684583

  • 1. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [Abstract] [Full Text] [Related]

  • 2. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
    Yates SW.
    Hosp Pract (1995); 2011 Oct; 39(4):7-16. PubMed ID: 22056819
    [Abstract] [Full Text] [Related]

  • 3. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S, Ansell J.
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [Abstract] [Full Text] [Related]

  • 4. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY, Larsen TB, Skjøth F, Rasmussen LH.
    J Am Coll Cardiol; 2012 Aug 21; 60(8):738-46. PubMed ID: 22575324
    [Abstract] [Full Text] [Related]

  • 5. Novel oral anticoagulants in secondary prevention of stroke.
    Diener HC, Easton JD, Hankey GJ, Hart RG.
    Best Pract Res Clin Haematol; 2013 Jun 21; 26(2):131-9. PubMed ID: 23953901
    [Abstract] [Full Text] [Related]

  • 6. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.
    Int Angiol; 2012 Aug 21; 31(4):330-9. PubMed ID: 22801398
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T, Cotté FE, Gaudin AF, Kachaner I, Kongnakorn T, Durand-Zaleski I.
    J Med Econ; 2014 Aug 21; 17(8):587-98. PubMed ID: 24831811
    [Abstract] [Full Text] [Related]

  • 15. Novel oral anticoagulants in non-valvular atrial fibrillation.
    Potpara TS, Lip GY.
    Best Pract Res Clin Haematol; 2013 Jun 21; 26(2):115-29. PubMed ID: 23953900
    [Abstract] [Full Text] [Related]

  • 16. A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE.
    Hess CN, Al-Khatib SM, Granger CB, Lopes R.
    Expert Rev Cardiovasc Ther; 2013 Sep 21; 11(9):1105-14. PubMed ID: 23992517
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
    Eikelboom JW, O'Donnell M, Yusuf S, Diaz R, Flaker G, Hart R, Hohnloser S, Joyner C, Lawrence J, Pais P, Pogue J, Synhorst D, Connolly SJ.
    Am Heart J; 2010 Mar 21; 159(3):348-353.e1. PubMed ID: 20211294
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
    Aguilar MI, Kuo RS, Freeman WD.
    Neurol Clin; 2013 Aug 21; 31(3):659-75. PubMed ID: 23896498
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 356.